#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=iSGLT2s are a new class of oral hypoglycaemic drugs that block glucose reabsorption at the renal level , thus promoting urine glucose and sodium excretion and reducing plasma glucose levels .
3-1	15-22	iSGLT2s	abstract	new	coref	3-3[4_0]
3-2	23-26	are	_	_	_	_
3-3	27-28	a	abstract[4]	giv[4]	coref	7-6[0_4]
3-4	29-32	new	abstract[4]	giv[4]	_	_
3-5	33-38	class	abstract[4]	giv[4]	_	_
3-6	39-41	of	abstract[4]	giv[4]	_	_
3-7	42-46	oral	abstract[4]|substance[5]	giv[4]|new[5]	coref	9-15[70_5]
3-8	47-60	hypoglycaemic	abstract[4]|substance[5]	giv[4]|new[5]	_	_
3-9	61-66	drugs	abstract[4]|substance[5]	giv[4]|new[5]	_	_
3-10	67-71	that	_	_	_	_
3-11	72-77	block	_	_	_	_
3-12	78-85	glucose	substance|event[7]	new|new[7]	coref|coref	3-21[11_0]|3-21[11_0]
3-13	86-98	reabsorption	event[7]	new[7]	_	_
3-14	99-101	at	_	_	_	_
3-15	102-105	the	abstract[9]	new[9]	_	_
3-16	106-111	renal	abstract|abstract[9]	new|new[9]	_	_
3-17	112-117	level	abstract[9]	new[9]	_	_
3-18	118-119	,	_	_	_	_
3-19	120-124	thus	_	_	_	_
3-20	125-134	promoting	_	_	_	_
3-21	135-140	urine	substance|substance[11]|abstract[12]	new|giv[11]|new[12]	coref|coref|coref|coref|coref|coref	3-29[0_11]|5-17[35_12]|3-29[0_11]|5-17[35_12]|3-29[0_11]|5-17[35_12]
3-22	141-148	glucose	substance[11]|abstract[12]	giv[11]|new[12]	_	_
3-23	149-152	and	abstract[12]	new[12]	_	_
3-24	153-159	sodium	abstract[12]|substance|abstract[14]	new[12]|new|new[14]	_	_
3-25	160-169	excretion	abstract[12]|abstract[14]	new[12]|new[14]	_	_
3-26	170-173	and	_	_	_	_
3-27	174-182	reducing	_	_	_	_
3-28	183-189	plasma	abstract|abstract[17]	new|new[17]	coref|coref|coref|coref	5-18|5-21[37_17]|5-18|5-21[37_17]
3-29	190-197	glucose	substance|abstract[17]	giv|new[17]	coref	5-17[34_0]
3-30	198-204	levels	abstract[17]	new[17]	_	_
3-31	205-206	.	_	_	_	_

#Text=In the present study , we have focused on the effects of empagliflozin on oxidative stress in the leukocytes of T2D subjects , and on inflammatory parameters .
4-1	207-209	In	_	_	_	_
4-2	210-213	the	event[18]	new[18]	coref	10-11[76_18]
4-3	214-221	present	event[18]	new[18]	_	_
4-4	222-227	study	event[18]	new[18]	_	_
4-5	228-229	,	_	_	_	_
4-6	230-232	we	person	acc	ana	5-24
4-7	233-237	have	_	_	_	_
4-8	238-245	focused	_	_	_	_
4-9	246-248	on	_	_	_	_
4-10	249-252	the	abstract[20]	new[20]	coref	12-16[98_20]
4-11	253-260	effects	abstract[20]	new[20]	_	_
4-12	261-263	of	abstract[20]	new[20]	_	_
4-13	264-277	empagliflozin	abstract[20]|substance	new[20]|new	coref	5-38[46_0]
4-14	278-280	on	abstract[20]	new[20]	_	_
4-15	281-290	oxidative	abstract[20]|abstract|abstract[23]	new[20]|new|new[23]	coref|coref|coref|coref	15-26[135_23]|19-16|15-26[135_23]|19-16
4-16	291-297	stress	abstract[20]|abstract[23]	new[20]|new[23]	_	_
4-17	298-300	in	abstract[20]|abstract[23]	new[20]|new[23]	_	_
4-18	301-304	the	abstract[20]|abstract[23]|person[24]	new[20]|new[23]|new[24]	_	_
4-19	305-315	leukocytes	abstract[20]|abstract[23]|person[24]	new[20]|new[23]|new[24]	_	_
4-20	316-318	of	abstract[20]|abstract[23]|person[24]	new[20]|new[23]|new[24]	_	_
4-21	319-322	T2D	abstract[20]|abstract[23]|person[24]|abstract|abstract[26]	new[20]|new[23]|new[24]|new|new[26]	coref|coref	14-17|14-17
4-22	323-331	subjects	abstract[20]|abstract[23]|person[24]|abstract[26]	new[20]|new[23]|new[24]|new[26]	_	_
4-23	332-333	,	_	_	_	_
4-24	334-337	and	_	_	_	_
4-25	338-340	on	_	_	_	_
4-26	341-353	inflammatory	abstract[27]	new[27]	coref	6-7[50_27]
4-27	354-364	parameters	abstract[27]	new[27]	_	_
4-28	365-366	.	_	_	_	_

#Text=In addition to a reduction in body weight and an improved metabolic profile — characterized by reduced plasma glucose and HbA1c levels — we observed a reduction in mitochondrial superoxide production in diabetic patients after treatment with the iSGLT2 empagliflozin , together with increased antioxidant defenses .
5-1	367-369	In	_	_	_	_
5-2	370-378	addition	_	_	_	_
5-3	379-381	to	_	_	_	_
5-4	382-383	a	abstract[28]	new[28]	coref	5-26[39_28]
5-5	384-393	reduction	abstract[28]	new[28]	_	_
5-6	394-396	in	abstract[28]	new[28]	_	_
5-7	397-401	body	abstract[28]|object|abstract[30]	new[28]|new|new[30]	coref|coref|coref|coref	12-22|12-22[101_30]|12-22|12-22[101_30]
5-8	402-408	weight	abstract[28]|abstract[30]	new[28]|new[30]	_	_
5-9	409-412	and	abstract[28]	new[28]	_	_
5-10	413-415	an	abstract[28]|abstract[32]	new[28]|new[32]	coref	7-10[59_32]
5-11	416-424	improved	abstract[28]|abstract[32]	new[28]|new[32]	_	_
5-12	425-434	metabolic	abstract[28]|person|abstract[32]	new[28]|new|new[32]	_	_
5-13	435-442	profile	abstract[28]|abstract[32]	new[28]|new[32]	_	_
5-14	443-444	—	_	_	_	_
5-15	445-458	characterized	_	_	_	_
5-16	459-461	by	_	_	_	_
5-17	462-469	reduced	substance[34]|abstract[35]	giv[34]|giv[35]	_	_
5-18	470-476	plasma	abstract|substance[34]|abstract[35]	giv|giv[34]|giv[35]	coref	22-6
5-19	477-484	glucose	substance[34]|abstract[35]	giv[34]|giv[35]	_	_
5-20	485-488	and	abstract[35]	giv[35]	_	_
5-21	489-494	HbA1c	abstract[35]|abstract|abstract[37]	giv[35]|new|giv[37]	coref|coref	11-7|11-7
5-22	495-501	levels	abstract[35]|abstract[37]	giv[35]|giv[37]	_	_
5-23	502-503	—	_	_	_	_
5-24	504-506	we	person	giv	ana	8-19
5-25	507-515	observed	_	_	_	_
5-26	516-517	a	abstract[39]	giv[39]	coref	10-17[77_39]
5-27	518-527	reduction	abstract[39]	giv[39]	_	_
5-28	528-530	in	abstract[39]	giv[39]	_	_
5-29	531-544	mitochondrial	abstract[39]|object|abstract[42]	giv[39]|new|new[42]	coref|coref|coref|coref	17-5[151_42]|20-14|17-5[151_42]|20-14
5-30	545-555	superoxide	abstract[39]|substance|abstract[42]	giv[39]|new|new[42]	coref	20-15
5-31	556-566	production	abstract[39]|abstract[42]	giv[39]|new[42]	_	_
5-32	567-569	in	abstract[39]|abstract[42]	giv[39]|new[42]	_	_
5-33	570-578	diabetic	abstract[39]|abstract[42]|person[43]	giv[39]|new[42]|new[43]	coref	14-17[123_43]
5-34	579-587	patients	abstract[39]|abstract[42]|person[43]	giv[39]|new[42]|new[43]	_	_
5-35	588-593	after	abstract[39]	giv[39]	_	_
5-36	594-603	treatment	abstract[39]|abstract[44]	giv[39]|new[44]	coref	6-16[52_44]
5-37	604-608	with	abstract[39]|abstract[44]	giv[39]|new[44]	_	_
5-38	609-612	the	abstract[39]|abstract[44]|substance[46]	giv[39]|new[44]|giv[46]	coref	6-18[0_46]
5-39	613-619	iSGLT2	abstract[39]|abstract[44]|object|substance[46]	giv[39]|new[44]|new|giv[46]	coref	12-11
5-40	620-633	empagliflozin	abstract[39]|abstract[44]|substance[46]	giv[39]|new[44]|giv[46]	_	_
5-41	634-635	,	abstract[39]|abstract[44]	giv[39]|new[44]	_	_
5-42	636-644	together	abstract[39]|abstract[44]|abstract[48]	giv[39]|new[44]|new[48]	coref	16-5[139_48]
5-43	645-649	with	abstract[39]|abstract[44]|abstract[48]	giv[39]|new[44]|new[48]	_	_
5-44	650-659	increased	abstract[39]|abstract[44]|abstract[48]	giv[39]|new[44]|new[48]	_	_
5-45	660-671	antioxidant	abstract[39]|abstract[44]|abstract|abstract[48]	giv[39]|new[44]|new|new[48]	coref	16-6
5-46	672-680	defenses	abstract[39]|abstract[44]|abstract[48]	giv[39]|new[44]|new[48]	_	_
5-47	681-682	.	_	_	_	_

#Text=Moreover , reduced proinflammatory markers and increased anti-inflammatory parameters were maintained after 24 weeks of treatment with empagliflozin .
6-1	683-691	Moreover	_	_	_	_
6-2	692-693	,	_	_	_	_
6-3	694-701	reduced	abstract[49]	new[49]	_	_
6-4	702-717	proinflammatory	abstract[49]	new[49]	_	_
6-5	718-725	markers	abstract[49]	new[49]	_	_
6-6	726-729	and	_	_	_	_
6-7	730-739	increased	abstract[50]	giv[50]	ana	7-2[0_50]
6-8	740-757	anti-inflammatory	abstract[50]	giv[50]	_	_
6-9	758-768	parameters	abstract[50]	giv[50]	_	_
6-10	769-773	were	_	_	_	_
6-11	774-784	maintained	_	_	_	_
6-12	785-790	after	_	_	_	_
6-13	791-793	24	time[51]	new[51]	_	_
6-14	794-799	weeks	time[51]	new[51]	_	_
6-15	800-802	of	time[51]	new[51]	_	_
6-16	803-812	treatment	time[51]|abstract[52]	new[51]|giv[52]	coref	8-1[61_52]
6-17	813-817	with	time[51]|abstract[52]	new[51]|giv[52]	_	_
6-18	818-831	empagliflozin	time[51]|abstract[52]|substance	new[51]|giv[52]|giv	coref	8-1
6-19	832-833	.	_	_	_	_

#Text=Besides their glucose-lowering effect , iSGLT2s produce changes in the lipid profile that should also be highlighted .
7-1	834-841	Besides	_	_	_	_
7-2	842-847	their	abstract|abstract[55]	giv|new[55]	coref|coref	19-11[176_55]|19-11[176_55]
7-3	848-864	glucose-lowering	abstract[55]	new[55]	_	_
7-4	865-871	effect	abstract[55]	new[55]	_	_
7-5	872-873	,	_	_	_	_
7-6	874-881	iSGLT2s	abstract	giv	coref	9-11
7-7	882-889	produce	_	_	_	_
7-8	890-897	changes	abstract	new	coref	22-3[203_0]
7-9	898-900	in	_	_	_	_
7-10	901-904	the	abstract[59]	giv[59]	_	_
7-11	905-910	lipid	abstract|abstract[59]	new|giv[59]	_	_
7-12	911-918	profile	abstract[59]	giv[59]	_	_
7-13	919-923	that	_	_	_	_
7-14	924-930	should	_	_	_	_
7-15	931-935	also	_	_	_	_
7-16	936-938	be	_	_	_	_
7-17	939-950	highlighted	_	_	_	_
7-18	951-952	.	_	_	_	_

#Text=Empagliflozin treatment is correlated with increased total cholesterol due to slight increases in HDL-c and LDL-c , as we have observed , and reported in other studies .
8-1	953-966	Empagliflozin	substance|abstract[61]	giv|giv[61]	coref|coref|coref|coref	10-28[81_0]|12-9[0_61]|10-28[81_0]|12-9[0_61]
8-2	967-976	treatment	abstract[61]	giv[61]	_	_
8-3	977-979	is	_	_	_	_
8-4	980-990	correlated	_	_	_	_
8-5	991-995	with	_	_	_	_
8-6	996-1005	increased	substance[62]	new[62]	_	_
8-7	1006-1011	total	substance[62]	new[62]	_	_
8-8	1012-1023	cholesterol	substance[62]	new[62]	_	_
8-9	1024-1027	due	_	_	_	_
8-10	1028-1030	to	_	_	_	_
8-11	1031-1037	slight	abstract[63]	new[63]	_	_
8-12	1038-1047	increases	abstract[63]	new[63]	_	_
8-13	1048-1050	in	abstract[63]	new[63]	_	_
8-14	1051-1056	HDL-c	abstract[63]|quantity	new[63]|new	_	_
8-15	1057-1060	and	abstract[63]	new[63]	_	_
8-16	1061-1066	LDL-c	abstract[63]|abstract	new[63]|new	_	_
8-17	1067-1068	,	_	_	_	_
8-18	1069-1071	as	_	_	_	_
8-19	1072-1074	we	person	giv	ana	20-1
8-20	1075-1079	have	_	_	_	_
8-21	1080-1088	observed	_	_	_	_
8-22	1089-1090	,	_	_	_	_
8-23	1091-1094	and	_	_	_	_
8-24	1095-1103	reported	_	_	_	_
8-25	1104-1106	in	_	_	_	_
8-26	1107-1112	other	abstract[67]	new[67]	coref	10-6[73_67]
8-27	1113-1120	studies	abstract[67]	new[67]	_	_
8-28	1121-1122	.	_	_	_	_

#Text=However , there is a well-documented cardiovascular protection exerted by iSGLT2s , which endows these drugs with clinical potential .
9-1	1123-1130	However	_	_	_	_
9-2	1131-1132	,	_	_	_	_
9-3	1133-1138	there	_	_	_	_
9-4	1139-1141	is	_	_	_	_
9-5	1142-1143	a	abstract[68]	new[68]	coref	11-34[92_68]
9-6	1144-1159	well-documented	abstract[68]	new[68]	_	_
9-7	1160-1174	cardiovascular	abstract[68]	new[68]	_	_
9-8	1175-1185	protection	abstract[68]	new[68]	_	_
9-9	1186-1193	exerted	_	_	_	_
9-10	1194-1196	by	_	_	_	_
9-11	1197-1204	iSGLT2s	object	giv	_	_
9-12	1205-1206	,	_	_	_	_
9-13	1207-1212	which	_	_	_	_
9-14	1213-1219	endows	_	_	_	_
9-15	1220-1225	these	substance[70]	giv[70]	_	_
9-16	1226-1231	drugs	substance[70]	giv[70]	_	_
9-17	1232-1236	with	_	_	_	_
9-18	1237-1245	clinical	abstract[71]	new[71]	ana	10-1[0_71]
9-19	1246-1255	potential	abstract[71]	new[71]	_	_
9-20	1256-1257	.	_	_	_	_

#Text=This has been reflected by several studies , such as the EMPA-REG OUTCOME study in which a reduction of 38 % in cardiovascular mortality was evident in the empagliflozin vs. placebo group .
10-1	1258-1262	This	abstract	giv	_	_
10-2	1263-1266	has	_	_	_	_
10-3	1267-1271	been	_	_	_	_
10-4	1272-1281	reflected	_	_	_	_
10-5	1282-1284	by	_	_	_	_
10-6	1285-1292	several	abstract[73]	giv[73]	coref	18-21[172_73]
10-7	1293-1300	studies	abstract[73]	giv[73]	_	_
10-8	1301-1302	,	abstract[73]	giv[73]	_	_
10-9	1303-1307	such	abstract[73]	giv[73]	_	_
10-10	1308-1310	as	abstract[73]	giv[73]	_	_
10-11	1311-1314	the	abstract[73]|event[76]	giv[73]|giv[76]	coref	11-10[86_76]
10-12	1315-1323	EMPA-REG	abstract[73]|organization|event[76]	giv[73]|new|giv[76]	coref	13-21
10-13	1324-1331	OUTCOME	abstract[73]|abstract|event[76]	giv[73]|new|giv[76]	coref	13-22
10-14	1332-1337	study	abstract[73]|event[76]	giv[73]|giv[76]	_	_
10-15	1338-1340	in	_	_	_	_
10-16	1341-1346	which	_	_	_	_
10-17	1347-1348	a	abstract[77]	giv[77]	coref	11-4[84_77]
10-18	1349-1358	reduction	abstract[77]	giv[77]	_	_
10-19	1359-1361	of	abstract[77]	giv[77]	_	_
10-20	1362-1364	38	abstract[77]|quantity[78]	giv[77]|new[78]	_	_
10-21	1365-1366	%	abstract[77]|quantity[78]	giv[77]|new[78]	_	_
10-22	1367-1369	in	abstract[77]|quantity[78]	giv[77]|new[78]	_	_
10-23	1370-1384	cardiovascular	abstract[77]|quantity[78]|abstract|event[80]	giv[77]|new[78]|new|new[80]	coref|coref|coref|coref	11-38|11-38[94_80]|11-38|11-38[94_80]
10-24	1385-1394	mortality	abstract[77]|quantity[78]|event[80]	giv[77]|new[78]|new[80]	_	_
10-25	1395-1398	was	_	_	_	_
10-26	1399-1406	evident	_	_	_	_
10-27	1407-1409	in	_	_	_	_
10-28	1410-1413	the	substance[81]	giv[81]	coref	13-18[112_81]
10-29	1414-1427	empagliflozin	substance[81]	giv[81]	_	_
10-30	1428-1431	vs.	substance[81]	giv[81]	_	_
10-31	1432-1439	placebo	substance[81]|person|abstract[83]	giv[81]|new|new[83]	_	_
10-32	1440-1445	group	substance[81]|abstract[83]	giv[81]|new[83]	_	_
10-33	1446-1447	.	_	_	_	_

#Text=However , neither the reduction in HbA1c observed in the study ( 0.60 % over 12 weeks ) nor the reduction in SBP ( up to 5 mmHg ) are sufficient to explain the reported protection against cardiovascular mortality .
11-1	1448-1455	However	_	_	_	_
11-2	1456-1457	,	_	_	_	_
11-3	1458-1465	neither	_	_	_	_
11-4	1466-1469	the	abstract[84]	giv[84]	coref	11-20[89_84]
11-5	1470-1479	reduction	abstract[84]	giv[84]	_	_
11-6	1480-1482	in	abstract[84]	giv[84]	_	_
11-7	1483-1488	HbA1c	abstract[84]|substance	giv[84]|giv	coref	12-20
11-8	1489-1497	observed	_	_	_	_
11-9	1498-1500	in	_	_	_	_
11-10	1501-1504	the	event[86]	giv[86]	coref	13-20[115_86]
11-11	1505-1510	study	event[86]	giv[86]	_	_
11-12	1511-1512	(	_	_	_	_
11-13	1513-1517	0.60	quantity[87]	new[87]	_	_
11-14	1518-1519	%	quantity[87]	new[87]	_	_
11-15	1520-1524	over	time[88]	new[88]	_	_
11-16	1525-1527	12	time[88]	new[88]	_	_
11-17	1528-1533	weeks	time[88]	new[88]	_	_
11-18	1534-1535	)	_	_	_	_
11-19	1536-1539	nor	_	_	_	_
11-20	1540-1543	the	abstract[89]	giv[89]	coref	13-5[106_89]
11-21	1544-1553	reduction	abstract[89]	giv[89]	_	_
11-22	1554-1556	in	abstract[89]	giv[89]	_	_
11-23	1557-1560	SBP	abstract[89]|substance	giv[89]|new	_	_
11-24	1561-1562	(	abstract[89]	giv[89]	_	_
11-25	1563-1565	up	abstract[89]	giv[89]	_	_
11-26	1566-1568	to	abstract[89]	giv[89]	_	_
11-27	1569-1570	5	abstract[89]|quantity[91]	giv[89]|new[91]	ana	12-16[0_91]
11-28	1571-1575	mmHg	abstract[89]|quantity[91]	giv[89]|new[91]	_	_
11-29	1576-1577	)	abstract[89]	giv[89]	_	_
11-30	1578-1581	are	_	_	_	_
11-31	1582-1592	sufficient	_	_	_	_
11-32	1593-1595	to	_	_	_	_
11-33	1596-1603	explain	_	_	_	_
11-34	1604-1607	the	abstract[92]	giv[92]	coref	15-12[131_92]
11-35	1608-1616	reported	abstract[92]	giv[92]	_	_
11-36	1617-1627	protection	abstract[92]	giv[92]	_	_
11-37	1628-1635	against	abstract[92]	giv[92]	_	_
11-38	1636-1650	cardiovascular	abstract[92]|abstract|abstract[94]	giv[92]|giv|giv[94]	coref|coref	12-34|12-34
11-39	1651-1660	mortality	abstract[92]|abstract[94]	giv[92]|giv[94]	_	_
11-40	1661-1662	.	_	_	_	_

#Text=Interestingly , as little as 24 weeks of treatment with iSGLT2 is sufficient to witness their beneficial effects on HbA1c , body weight , blood pressure and , most importantly , on the cardiovascular system .
12-1	1663-1676	Interestingly	_	_	_	_
12-2	1677-1678	,	_	_	_	_
12-3	1679-1681	as	_	_	_	_
12-4	1682-1688	little	_	_	_	_
12-5	1689-1691	as	_	_	_	_
12-6	1692-1694	24	_	_	_	_
12-7	1695-1700	weeks	_	_	_	_
12-8	1701-1703	of	_	_	_	_
12-9	1704-1713	treatment	abstract	giv	coref	14-13
12-10	1714-1718	with	_	_	_	_
12-11	1719-1725	iSGLT2	abstract	giv	coref	15-17
12-12	1726-1728	is	_	_	_	_
12-13	1729-1739	sufficient	_	_	_	_
12-14	1740-1742	to	_	_	_	_
12-15	1743-1750	witness	_	_	_	_
12-16	1751-1756	their	quantity|abstract[98]	giv|giv[98]	_	_
12-17	1757-1767	beneficial	abstract[98]	giv[98]	_	_
12-18	1768-1775	effects	abstract[98]	giv[98]	_	_
12-19	1776-1778	on	abstract[98]	giv[98]	_	_
12-20	1779-1784	HbA1c	abstract[98]|substance	giv[98]|giv	_	_
12-21	1785-1786	,	abstract[98]	giv[98]	_	_
12-22	1787-1791	body	abstract[98]|object|object[101]	giv[98]|giv|giv[101]	_	_
12-23	1792-1798	weight	abstract[98]|object[101]	giv[98]|giv[101]	_	_
12-24	1799-1800	,	abstract[98]	giv[98]	_	_
12-25	1801-1806	blood	abstract[98]|abstract[102]	giv[98]|new[102]	_	_
12-26	1807-1815	pressure	abstract[98]|abstract[102]	giv[98]|new[102]	_	_
12-27	1816-1819	and	_	_	_	_
12-28	1820-1821	,	_	_	_	_
12-29	1822-1826	most	abstract[104]	new[104]	coref	17-11[155_104]
12-30	1827-1838	importantly	abstract[104]	new[104]	_	_
12-31	1839-1840	,	abstract[104]	new[104]	_	_
12-32	1841-1843	on	abstract[104]	new[104]	_	_
12-33	1844-1847	the	abstract[104]	new[104]	_	_
12-34	1848-1862	cardiovascular	abstract|abstract[104]	giv|new[104]	coref	15-13
12-35	1863-1869	system	abstract[104]	new[104]	_	_
12-36	1870-1871	.	_	_	_	_

#Text=As an example , the reduction in hospitalization rates for heart failure in the group treated with empagliflozin in the EMPA-REG OUTCOME study was already significant at this time point .
13-1	1872-1874	As	_	_	_	_
13-2	1875-1877	an	abstract[105]	new[105]	_	_
13-3	1878-1885	example	abstract[105]	new[105]	_	_
13-4	1886-1887	,	_	_	_	_
13-5	1888-1891	the	abstract[106]	giv[106]	_	_
13-6	1892-1901	reduction	abstract[106]	giv[106]	_	_
13-7	1902-1904	in	abstract[106]	giv[106]	_	_
13-8	1905-1920	hospitalization	abstract[106]|abstract|abstract[108]	giv[106]|new|new[108]	_	_
13-9	1921-1926	rates	abstract[106]|abstract[108]	giv[106]|new[108]	_	_
13-10	1927-1930	for	abstract[106]|abstract[108]	giv[106]|new[108]	_	_
13-11	1931-1936	heart	abstract[106]|abstract[108]|object|event[110]	giv[106]|new[108]|new|new[110]	_	_
13-12	1937-1944	failure	abstract[106]|abstract[108]|event[110]	giv[106]|new[108]|new[110]	_	_
13-13	1945-1947	in	abstract[106]|abstract[108]|event[110]	giv[106]|new[108]|new[110]	_	_
13-14	1948-1951	the	abstract[106]|abstract[108]|event[110]|person[111]	giv[106]|new[108]|new[110]|new[111]	_	_
13-15	1952-1957	group	abstract[106]|abstract[108]|event[110]|person[111]	giv[106]|new[108]|new[110]|new[111]	_	_
13-16	1958-1965	treated	_	_	_	_
13-17	1966-1970	with	_	_	_	_
13-18	1971-1984	empagliflozin	substance[112]	giv[112]	coref	14-15[121_112]
13-19	1985-1987	in	substance[112]	giv[112]	_	_
13-20	1988-1991	the	substance[112]|event[115]	giv[112]|giv[115]	coref	14-1[117_115]
13-21	1992-2000	EMPA-REG	substance[112]|organization|event[115]	giv[112]|giv|giv[115]	_	_
13-22	2001-2008	OUTCOME	substance[112]|abstract|event[115]	giv[112]|giv|giv[115]	_	_
13-23	2009-2014	study	substance[112]|event[115]	giv[112]|giv[115]	_	_
13-24	2015-2018	was	_	_	_	_
13-25	2019-2026	already	_	_	_	_
13-26	2027-2038	significant	_	_	_	_
13-27	2039-2041	at	_	_	_	_
13-28	2042-2046	this	time[116]	new[116]	_	_
13-29	2047-2051	time	time[116]	new[116]	_	_
13-30	2052-2057	point	time[116]	new[116]	_	_
13-31	2058-2059	.	_	_	_	_

#Text=A recent study demonstrated an improved arterial stiffness after 6 weeks of treatment with empagliflozin in T2D patients , and hs-CRP was shown to be one of the main significant determinants for this improvement .
14-1	2060-2061	A	event[117]	giv[117]	_	_
14-2	2062-2068	recent	event[117]	giv[117]	_	_
14-3	2069-2074	study	event[117]	giv[117]	_	_
14-4	2075-2087	demonstrated	_	_	_	_
14-5	2088-2090	an	abstract[118]	new[118]	_	_
14-6	2091-2099	improved	abstract[118]	new[118]	_	_
14-7	2100-2108	arterial	abstract[118]	new[118]	_	_
14-8	2109-2118	stiffness	abstract[118]	new[118]	_	_
14-9	2119-2124	after	abstract[118]	new[118]	_	_
14-10	2125-2126	6	abstract[118]|time[119]	new[118]|new[119]	_	_
14-11	2127-2132	weeks	abstract[118]|time[119]	new[118]|new[119]	_	_
14-12	2133-2135	of	abstract[118]|time[119]	new[118]|new[119]	_	_
14-13	2136-2145	treatment	abstract[118]|time[119]|abstract	new[118]|new[119]|giv	coref	15-17[133_0]
14-14	2146-2150	with	abstract[118]|time[119]	new[118]|new[119]	_	_
14-15	2151-2164	empagliflozin	abstract[118]|time[119]|substance[121]	new[118]|new[119]|giv[121]	coref	22-13[0_121]
14-16	2165-2167	in	abstract[118]|time[119]|substance[121]	new[118]|new[119]|giv[121]	_	_
14-17	2168-2171	T2D	abstract[118]|time[119]|substance[121]|abstract|person[123]	new[118]|new[119]|giv[121]|giv|giv[123]	coref|coref|coref|coref	16-30|20-5[185_123]|16-30|20-5[185_123]
14-18	2172-2180	patients	abstract[118]|time[119]|substance[121]|person[123]	new[118]|new[119]|giv[121]|giv[123]	_	_
14-19	2181-2182	,	_	_	_	_
14-20	2183-2186	and	_	_	_	_
14-21	2187-2193	hs-CRP	abstract	new	_	_
14-22	2194-2197	was	_	_	_	_
14-23	2198-2203	shown	_	_	_	_
14-24	2204-2206	to	_	_	_	_
14-25	2207-2209	be	_	_	_	_
14-26	2210-2213	one	abstract[125]	new[125]	_	_
14-27	2214-2216	of	abstract[125]	new[125]	_	_
14-28	2217-2220	the	abstract[125]|abstract[126]	new[125]|new[126]	_	_
14-29	2221-2225	main	abstract[125]|abstract[126]	new[125]|new[126]	_	_
14-30	2226-2237	significant	abstract[125]|abstract[126]	new[125]|new[126]	_	_
14-31	2238-2250	determinants	abstract[125]|abstract[126]	new[125]|new[126]	_	_
14-32	2251-2254	for	abstract[125]|abstract[126]	new[125]|new[126]	_	_
14-33	2255-2259	this	abstract[125]|abstract[126]|abstract[127]	new[125]|new[126]|new[127]	_	_
14-34	2260-2271	improvement	abstract[125]|abstract[126]|abstract[127]	new[125]|new[126]|new[127]	_	_
14-35	2272-2273	.	_	_	_	_

#Text=Nevertheless , despite the available evidence , the molecular mechanisms underlying the cardiovascular protection attributable to iSGLT2 treatment are still unknown , though amelioration of oxidative stress has been hypothesized to be a potential contributor .
15-1	2274-2286	Nevertheless	_	_	_	_
15-2	2287-2288	,	_	_	_	_
15-3	2289-2296	despite	_	_	_	_
15-4	2297-2300	the	abstract[128]	new[128]	_	_
15-5	2301-2310	available	abstract[128]	new[128]	_	_
15-6	2311-2319	evidence	abstract[128]	new[128]	_	_
15-7	2320-2321	,	_	_	_	_
15-8	2322-2325	the	abstract[129]	new[129]	_	_
15-9	2326-2335	molecular	abstract[129]	new[129]	_	_
15-10	2336-2346	mechanisms	abstract[129]	new[129]	_	_
15-11	2347-2357	underlying	_	_	_	_
15-12	2358-2361	the	abstract[131]	giv[131]	coref	16-22[146_131]
15-13	2362-2376	cardiovascular	abstract|abstract[131]	giv|giv[131]	_	_
15-14	2377-2387	protection	abstract[131]	giv[131]	_	_
15-15	2388-2400	attributable	_	_	_	_
15-16	2401-2403	to	_	_	_	_
15-17	2404-2410	iSGLT2	object|abstract[133]	giv|giv[133]	coref|coref|coref|coref	19-14[177_0]|20-8[187_133]|19-14[177_0]|20-8[187_133]
15-18	2411-2420	treatment	abstract[133]	giv[133]	_	_
15-19	2421-2424	are	_	_	_	_
15-20	2425-2430	still	_	_	_	_
15-21	2431-2438	unknown	_	_	_	_
15-22	2439-2440	,	_	_	_	_
15-23	2441-2447	though	_	_	_	_
15-24	2448-2460	amelioration	abstract[134]	new[134]	_	_
15-25	2461-2463	of	abstract[134]	new[134]	_	_
15-26	2464-2473	oxidative	abstract[134]|abstract[135]	new[134]|giv[135]	coref	17-1[150_135]
15-27	2474-2480	stress	abstract[134]|abstract[135]	new[134]|giv[135]	_	_
15-28	2481-2484	has	_	_	_	_
15-29	2485-2489	been	_	_	_	_
15-30	2490-2502	hypothesized	_	_	_	_
15-31	2503-2505	to	_	_	_	_
15-32	2506-2508	be	_	_	_	_
15-33	2509-2510	a	abstract[136]	new[136]	_	_
15-34	2511-2520	potential	abstract[136]	new[136]	_	_
15-35	2521-2532	contributor	abstract[136]	new[136]	_	_
15-36	2533-2534	.	_	_	_	_

#Text=Because cardiac tissue possesses low antioxidant defenses , increasing the expression or activity of antioxidant enzymes could be a mechanism of cardiac protection under high risk situations such as T2D .
16-1	2535-2542	Because	_	_	_	_
16-2	2543-2550	cardiac	object[137]	new[137]	coref	17-35[0_137]
16-3	2551-2557	tissue	object[137]	new[137]	_	_
16-4	2558-2567	possesses	_	_	_	_
16-5	2568-2571	low	abstract[139]	giv[139]	_	_
16-6	2572-2583	antioxidant	abstract|abstract[139]	giv|giv[139]	coref	16-15
16-7	2584-2592	defenses	abstract[139]	giv[139]	_	_
16-8	2593-2594	,	_	_	_	_
16-9	2595-2605	increasing	_	_	_	_
16-10	2606-2609	the	abstract[140]	new[140]	coref	21-5[198_140]
16-11	2610-2620	expression	abstract[140]	new[140]	_	_
16-12	2621-2623	or	_	_	_	_
16-13	2624-2632	activity	abstract[141]	new[141]	coref	24-22[225_141]
16-14	2633-2635	of	abstract[141]	new[141]	_	_
16-15	2636-2647	antioxidant	abstract[141]|abstract|substance[143]	new[141]|giv|new[143]	coref|coref|coref|coref	21-9|21-8[200_143]|21-9|21-8[200_143]
16-16	2648-2655	enzymes	abstract[141]|substance[143]	new[141]|new[143]	_	_
16-17	2656-2661	could	_	_	_	_
16-18	2662-2664	be	_	_	_	_
16-19	2665-2666	a	abstract[144]	new[144]	_	_
16-20	2667-2676	mechanism	abstract[144]	new[144]	_	_
16-21	2677-2679	of	abstract[144]	new[144]	_	_
16-22	2680-2687	cardiac	abstract[144]|person|abstract[146]	new[144]|new|giv[146]	_	_
16-23	2688-2698	protection	abstract[144]|abstract[146]	new[144]|giv[146]	_	_
16-24	2699-2704	under	abstract[144]|abstract[146]	new[144]|giv[146]	_	_
16-25	2705-2709	high	abstract[144]|abstract[146]|abstract[148]	new[144]|giv[146]|new[148]	_	_
16-26	2710-2714	risk	abstract[144]|abstract[146]|abstract|abstract[148]	new[144]|giv[146]|new|new[148]	_	_
16-27	2715-2725	situations	abstract[144]|abstract[146]|abstract[148]	new[144]|giv[146]|new[148]	_	_
16-28	2726-2730	such	abstract[144]|abstract[146]|abstract[148]	new[144]|giv[146]|new[148]	_	_
16-29	2731-2733	as	abstract[144]|abstract[146]|abstract[148]	new[144]|giv[146]|new[148]	_	_
16-30	2734-2737	T2D	abstract[144]|abstract[146]|abstract[148]|abstract	new[144]|giv[146]|new[148]|giv	coref	20-5
16-31	2738-2739	.	_	_	_	_

#Text=Oxidative stress occurs when the production of pro-oxidant species overcomes the intrinsic antioxidant defense system of the cell , thus triggering damage to lipids , proteins and DNA , and eventually compromising cellular and tissue function .
17-1	2740-2749	Oxidative	abstract[150]	giv[150]	coref	18-14[0_150]
17-2	2750-2756	stress	abstract[150]	giv[150]	_	_
17-3	2757-2763	occurs	_	_	_	_
17-4	2764-2768	when	_	_	_	_
17-5	2769-2772	the	abstract[151]	giv[151]	coref	20-14[191_151]
17-6	2773-2783	production	abstract[151]	giv[151]	_	_
17-7	2784-2786	of	abstract[151]	giv[151]	_	_
17-8	2787-2798	pro-oxidant	abstract[151]|plant[152]	giv[151]|new[152]	_	_
17-9	2799-2806	species	abstract[151]|plant[152]	giv[151]|new[152]	_	_
17-10	2807-2816	overcomes	_	_	_	_
17-11	2817-2820	the	abstract[155]	giv[155]	_	_
17-12	2821-2830	intrinsic	abstract[155]	giv[155]	_	_
17-13	2831-2842	antioxidant	person|abstract[155]	new|giv[155]	coref	24-18
17-14	2843-2850	defense	abstract|abstract[155]	new|giv[155]	_	_
17-15	2851-2857	system	abstract[155]	giv[155]	_	_
17-16	2858-2860	of	abstract[155]	giv[155]	_	_
17-17	2861-2864	the	abstract[155]|object[156]	giv[155]|new[156]	_	_
17-18	2865-2869	cell	abstract[155]|object[156]	giv[155]|new[156]	_	_
17-19	2870-2871	,	_	_	_	_
17-20	2872-2876	thus	_	_	_	_
17-21	2877-2887	triggering	_	_	_	_
17-22	2888-2894	damage	abstract[157]	new[157]	_	_
17-23	2895-2897	to	abstract[157]	new[157]	_	_
17-24	2898-2904	lipids	abstract[157]|substance	new[157]|new	_	_
17-25	2905-2906	,	abstract[157]	new[157]	_	_
17-26	2907-2915	proteins	abstract[157]|substance	new[157]|new	_	_
17-27	2916-2919	and	abstract[157]	new[157]	_	_
17-28	2920-2923	DNA	abstract[157]|substance	new[157]|new	_	_
17-29	2924-2925	,	_	_	_	_
17-30	2926-2929	and	_	_	_	_
17-31	2930-2940	eventually	_	_	_	_
17-32	2941-2953	compromising	_	_	_	_
17-33	2954-2962	cellular	abstract	new	_	_
17-34	2963-2966	and	_	_	_	_
17-35	2967-2973	tissue	object|abstract[163]	giv|new[163]	coref|coref	25-24[239_0]|25-24[239_0]
17-36	2974-2982	function	abstract[163]	new[163]	_	_
17-37	2983-2984	.	_	_	_	_

#Text=Exploring the role of SGLT2 inhibition in the prevention or reduction of oxidative stress conditions has been the subject of several studies over the last decade .
18-1	2985-2994	Exploring	_	_	_	_
18-2	2995-2998	the	abstract[164]	new[164]	_	_
18-3	2999-3003	role	abstract[164]	new[164]	_	_
18-4	3004-3006	of	abstract[164]	new[164]	_	_
18-5	3007-3012	SGLT2	abstract[164]|abstract|abstract[166]	new[164]|new|new[166]	_	_
18-6	3013-3023	inhibition	abstract[164]|abstract[166]	new[164]|new[166]	_	_
18-7	3024-3026	in	abstract[164]|abstract[166]	new[164]|new[166]	_	_
18-8	3027-3030	the	abstract[164]|abstract[166]|abstract[167]	new[164]|new[166]|new[167]	_	_
18-9	3031-3041	prevention	abstract[164]|abstract[166]|abstract[167]	new[164]|new[166]|new[167]	_	_
18-10	3042-3044	or	abstract[164]|abstract[166]	new[164]|new[166]	_	_
18-11	3045-3054	reduction	abstract[164]|abstract[166]|abstract[168]	new[164]|new[166]|new[168]	coref	20-11[188_168]
18-12	3055-3057	of	abstract[164]|abstract[166]|abstract[168]	new[164]|new[166]|new[168]	_	_
18-13	3058-3067	oxidative	abstract[164]|abstract[166]|abstract[168]|abstract[170]	new[164]|new[166]|new[168]|new[170]	_	_
18-14	3068-3074	stress	abstract[164]|abstract[166]|abstract[168]|abstract|abstract[170]	new[164]|new[166]|new[168]|giv|new[170]	coref	19-16[179_0]
18-15	3075-3085	conditions	abstract[164]|abstract[166]|abstract[168]|abstract[170]	new[164]|new[166]|new[168]|new[170]	_	_
18-16	3086-3089	has	_	_	_	_
18-17	3090-3094	been	_	_	_	_
18-18	3095-3098	the	abstract[171]	new[171]	_	_
18-19	3099-3106	subject	abstract[171]	new[171]	_	_
18-20	3107-3109	of	abstract[171]	new[171]	_	_
18-21	3110-3117	several	abstract[171]|abstract[172]	new[171]|giv[172]	coref	19-6[175_172]
18-22	3118-3125	studies	abstract[171]|abstract[172]	new[171]|giv[172]	_	_
18-23	3126-3130	over	abstract[171]|abstract[172]	new[171]|giv[172]	_	_
18-24	3131-3134	the	abstract[171]|abstract[172]|time[173]	new[171]|giv[172]|new[173]	_	_
18-25	3135-3139	last	abstract[171]|abstract[172]|time[173]	new[171]|giv[172]|new[173]	_	_
18-26	3140-3146	decade	abstract[171]|abstract[172]|time[173]	new[171]|giv[172]|new[173]	_	_
18-27	3147-3148	.	_	_	_	_

#Text=However , to date , most of the studies evaluating the effect of iSGLT2 on oxidative stress have been performed in animal models .
19-1	3149-3156	However	_	_	_	_
19-2	3157-3158	,	_	_	_	_
19-3	3159-3161	to	_	_	_	_
19-4	3162-3166	date	time	new	_	_
19-5	3167-3168	,	_	_	_	_
19-6	3169-3173	most	abstract[175]	giv[175]	coref	24-7[219_175]
19-7	3174-3176	of	abstract[175]	giv[175]	_	_
19-8	3177-3180	the	abstract[175]	giv[175]	_	_
19-9	3181-3188	studies	abstract[175]	giv[175]	_	_
19-10	3189-3199	evaluating	_	_	_	_
19-11	3200-3203	the	abstract[176]	giv[176]	_	_
19-12	3204-3210	effect	abstract[176]	giv[176]	_	_
19-13	3211-3213	of	abstract[176]	giv[176]	_	_
19-14	3214-3220	iSGLT2	abstract[176]|object[177]	giv[176]|giv[177]	coref	20-8[0_177]
19-15	3221-3223	on	abstract[176]|object[177]	giv[176]|giv[177]	_	_
19-16	3224-3233	oxidative	abstract[176]|object[177]|abstract|abstract[179]	giv[176]|giv[177]|giv|giv[179]	_	_
19-17	3234-3240	stress	abstract[176]|object[177]|abstract[179]	giv[176]|giv[177]|giv[179]	_	_
19-18	3241-3245	have	_	_	_	_
19-19	3246-3250	been	_	_	_	_
19-20	3251-3260	performed	_	_	_	_
19-21	3261-3263	in	_	_	_	_
19-22	3264-3270	animal	person|abstract[181]	new|new[181]	coref|coref	24-10[220_181]|24-10[220_181]
19-23	3271-3277	models	abstract[181]	new[181]	_	_
19-24	3278-3279	.	_	_	_	_

#Text=Our data demonstrate that T2D patients receiving iSGLT2 treatment undergo a reduction in mitochondrial superoxide production in parallel to an increase in glutathione content , and markedly so after 24 weeks of treatment .
20-1	3280-3283	Our	person|abstract[183]	giv|new[183]	ana|ana	24-1|24-1
20-2	3284-3288	data	abstract[183]	new[183]	_	_
20-3	3289-3300	demonstrate	_	_	_	_
20-4	3301-3305	that	_	_	_	_
20-5	3306-3309	T2D	abstract|person[185]	giv|giv[185]	coref|coref	24-13|24-13
20-6	3310-3318	patients	person[185]	giv[185]	_	_
20-7	3319-3328	receiving	_	_	_	_
20-8	3329-3335	iSGLT2	abstract|abstract[187]	giv|giv[187]	coref|coref|coref|coref	20-33[0_187]|25-3|20-33[0_187]|25-3
20-9	3336-3345	treatment	abstract[187]	giv[187]	_	_
20-10	3346-3353	undergo	_	_	_	_
20-11	3354-3355	a	abstract[188]	giv[188]	_	_
20-12	3356-3365	reduction	abstract[188]	giv[188]	_	_
20-13	3366-3368	in	abstract[188]	giv[188]	_	_
20-14	3369-3382	mitochondrial	abstract[188]|object|abstract[191]	giv[188]|giv|giv[191]	ana|ana	21-1[0_191]|21-1[0_191]
20-15	3383-3393	superoxide	abstract[188]|substance|abstract[191]	giv[188]|giv|giv[191]	coref	25-18
20-16	3394-3404	production	abstract[188]|abstract[191]	giv[188]|giv[191]	_	_
20-17	3405-3407	in	abstract[188]|abstract[191]	giv[188]|giv[191]	_	_
20-18	3408-3416	parallel	abstract[188]|abstract[191]	giv[188]|giv[191]	_	_
20-19	3417-3419	to	_	_	_	_
20-20	3420-3422	an	event[192]	new[192]	_	_
20-21	3423-3431	increase	event[192]	new[192]	_	_
20-22	3432-3434	in	event[192]	new[192]	_	_
20-23	3435-3446	glutathione	event[192]|substance|abstract[194]	new[192]|new|new[194]	coref|coref	22-6[207_194]|22-6[207_194]
20-24	3447-3454	content	event[192]|abstract[194]	new[192]|new[194]	_	_
20-25	3455-3456	,	_	_	_	_
20-26	3457-3460	and	_	_	_	_
20-27	3461-3469	markedly	time[195]	new[195]	_	_
20-28	3470-3472	so	time[195]	new[195]	_	_
20-29	3473-3478	after	time[195]	new[195]	_	_
20-30	3479-3481	24	time[195]	new[195]	_	_
20-31	3482-3487	weeks	time[195]	new[195]	_	_
20-32	3488-3490	of	time[195]	new[195]	_	_
20-33	3491-3500	treatment	time[195]|abstract	new[195]|giv	coref	22-13[209_0]
20-34	3501-3502	.	_	_	_	_

#Text=This is accompanied by increased expression of the antioxidant enzymes GSR and CAT .
21-1	3503-3507	This	abstract	giv	_	_
21-2	3508-3510	is	_	_	_	_
21-3	3511-3522	accompanied	_	_	_	_
21-4	3523-3525	by	_	_	_	_
21-5	3526-3535	increased	abstract[198]	giv[198]	coref	25-13[233_198]
21-6	3536-3546	expression	abstract[198]	giv[198]	_	_
21-7	3547-3549	of	abstract[198]	giv[198]	_	_
21-8	3550-3553	the	abstract[198]|substance[200]	giv[198]|giv[200]	_	_
21-9	3554-3565	antioxidant	abstract[198]|abstract|substance[200]	giv[198]|giv|giv[200]	_	_
21-10	3566-3573	enzymes	abstract[198]|substance[200]	giv[198]|giv[200]	_	_
21-11	3574-3577	GSR	abstract[198]|substance[200]|abstract	giv[198]|giv[200]|new	_	_
21-12	3578-3581	and	abstract[198]|substance[200]	giv[198]|giv[200]	_	_
21-13	3582-3585	CAT	abstract[198]|substance[200]|object	giv[198]|giv[200]|new	coref	25-21
21-14	3586-3587	.	_	_	_	_

#Text=However , no changes in plasma protein carbonyl content were observed with empagliflozin treatment at these time-points .
22-1	3588-3595	However	_	_	_	_
22-2	3596-3597	,	_	_	_	_
22-3	3598-3600	no	abstract[203]	giv[203]	_	_
22-4	3601-3608	changes	abstract[203]	giv[203]	_	_
22-5	3609-3611	in	abstract[203]	giv[203]	_	_
22-6	3612-3618	plasma	abstract[203]|object|substance[205]|abstract[207]	giv[203]|giv|new[205]|giv[207]	coref|coref|coref	24-18[224_207]|24-18[224_207]|24-18[224_207]
22-7	3619-3626	protein	abstract[203]|substance[205]|abstract[207]	giv[203]|new[205]|giv[207]	_	_
22-8	3627-3635	carbonyl	abstract[203]|abstract|abstract[207]	giv[203]|new|giv[207]	_	_
22-9	3636-3643	content	abstract[203]|abstract[207]	giv[203]|giv[207]	_	_
22-10	3644-3648	were	_	_	_	_
22-11	3649-3657	observed	_	_	_	_
22-12	3658-3662	with	_	_	_	_
22-13	3663-3676	empagliflozin	substance|abstract[209]	giv|giv[209]	ana|coref|ana|coref	23-2[0_209]|23-15|23-2[0_209]|23-15
22-14	3677-3686	treatment	abstract[209]	giv[209]	_	_
22-15	3687-3689	at	abstract[209]	giv[209]	_	_
22-16	3690-3695	these	abstract[209]|time[210]	giv[209]|new[210]	_	_
22-17	3696-3707	time-points	abstract[209]|time[210]	giv[209]|new[210]	_	_
22-18	3708-3709	.	_	_	_	_

#Text=Whether this could be due to the small sample size or would require long-term empagliflozin treatment needs to be addressed in future research .
23-1	3710-3717	Whether	_	_	_	_
23-2	3718-3722	this	abstract	giv	coref	23-14[215_0]
23-3	3723-3728	could	_	_	_	_
23-4	3729-3731	be	_	_	_	_
23-5	3732-3735	due	_	_	_	_
23-6	3736-3738	to	_	_	_	_
23-7	3739-3742	the	quantity[213]	new[213]	_	_
23-8	3743-3748	small	quantity[213]	new[213]	_	_
23-9	3749-3755	sample	object|quantity[213]	new|new[213]	_	_
23-10	3756-3760	size	quantity[213]	new[213]	_	_
23-11	3761-3763	or	_	_	_	_
23-12	3764-3769	would	_	_	_	_
23-13	3770-3777	require	_	_	_	_
23-14	3778-3787	long-term	abstract[215]	giv[215]	coref	25-3[229_215]
23-15	3788-3801	empagliflozin	substance|abstract[215]	giv|giv[215]	_	_
23-16	3802-3811	treatment	abstract[215]	giv[215]	_	_
23-17	3812-3817	needs	_	_	_	_
23-18	3818-3820	to	_	_	_	_
23-19	3821-3823	be	_	_	_	_
23-20	3824-3833	addressed	_	_	_	_
23-21	3834-3836	in	_	_	_	_
23-22	3837-3843	future	abstract[216]	new[216]	_	_
23-23	3844-3852	research	abstract[216]	new[216]	_	_
23-24	3853-3854	.	_	_	_	_

#Text=Our findings are in accordance with previous studies in rat models of T2D , in which increased antioxidant enzyme content and activity in renal tissues has been reported .
24-1	3855-3858	Our	person|abstract[218]	giv|new[218]	_	_
24-2	3859-3867	findings	abstract[218]	new[218]	_	_
24-3	3868-3871	are	_	_	_	_
24-4	3872-3874	in	_	_	_	_
24-5	3875-3885	accordance	_	_	_	_
24-6	3886-3890	with	_	_	_	_
24-7	3891-3899	previous	abstract[219]	giv[219]	_	_
24-8	3900-3907	studies	abstract[219]	giv[219]	_	_
24-9	3908-3910	in	abstract[219]	giv[219]	_	_
24-10	3911-3914	rat	abstract[219]|abstract[220]	giv[219]|giv[220]	_	_
24-11	3915-3921	models	abstract[219]|abstract[220]	giv[219]|giv[220]	_	_
24-12	3922-3924	of	abstract[219]|abstract[220]	giv[219]|giv[220]	_	_
24-13	3925-3928	T2D	abstract[219]|abstract[220]|abstract	giv[219]|giv[220]|giv	_	_
24-14	3929-3930	,	_	_	_	_
24-15	3931-3933	in	_	_	_	_
24-16	3934-3939	which	_	_	_	_
24-17	3940-3949	increased	_	_	_	_
24-18	3950-3961	antioxidant	person|abstract[224]	giv|giv[224]	coref|coref	25-13|25-13
24-19	3962-3968	enzyme	substance|abstract[224]	new|giv[224]	_	_
24-20	3969-3976	content	abstract[224]	giv[224]	_	_
24-21	3977-3980	and	_	_	_	_
24-22	3981-3989	activity	abstract[225]	giv[225]	_	_
24-23	3990-3992	in	abstract[225]	giv[225]	_	_
24-24	3993-3998	renal	abstract[225]|abstract|object[227]	giv[225]|new|new[227]	_	_
24-25	3999-4006	tissues	abstract[225]|object[227]	giv[225]|new[227]	_	_
24-26	4007-4010	has	_	_	_	_
24-27	4011-4015	been	_	_	_	_
24-28	4016-4024	reported	_	_	_	_
24-29	4025-4026	.	_	_	_	_

#Text=Furthermore , iSGLT2 treatment in diabetic mice has been shown to induce antioxidant gene expression ( manganese-dependent superoxide dismutase and CAT ) in adipose tissue and muscle .
25-1	4027-4038	Furthermore	_	_	_	_
25-2	4039-4040	,	_	_	_	_
25-3	4041-4047	iSGLT2	abstract|abstract[229]	giv|giv[229]	_	_
25-4	4048-4057	treatment	abstract[229]	giv[229]	_	_
25-5	4058-4060	in	abstract[229]	giv[229]	_	_
25-6	4061-4069	diabetic	abstract[229]|animal[230]	giv[229]|new[230]	_	_
25-7	4070-4074	mice	abstract[229]|animal[230]	giv[229]|new[230]	_	_
25-8	4075-4078	has	_	_	_	_
25-9	4079-4083	been	_	_	_	_
25-10	4084-4089	shown	_	_	_	_
25-11	4090-4092	to	_	_	_	_
25-12	4093-4099	induce	_	_	_	_
25-13	4100-4111	antioxidant	person|abstract[233]	giv|giv[233]	appos|appos	25-17[236_233]|25-17[236_233]
25-14	4112-4116	gene	abstract|abstract[233]	new|giv[233]	_	_
25-15	4117-4127	expression	abstract[233]	giv[233]	_	_
25-16	4128-4129	(	_	_	_	_
25-17	4130-4149	manganese-dependent	substance[235]|abstract[236]	new[235]|giv[236]	_	_
25-18	4150-4160	superoxide	substance|substance[235]|abstract[236]	giv|new[235]|giv[236]	_	_
25-19	4161-4170	dismutase	substance[235]|abstract[236]	new[235]|giv[236]	_	_
25-20	4171-4174	and	abstract[236]	giv[236]	_	_
25-21	4175-4178	CAT	abstract[236]|object	giv[236]|giv	_	_
25-22	4179-4180	)	_	_	_	_
25-23	4181-4183	in	_	_	_	_
25-24	4184-4191	adipose	abstract|object[239]	new|giv[239]	_	_
25-25	4192-4198	tissue	object[239]	giv[239]	_	_
25-26	4199-4202	and	_	_	_	_
25-27	4203-4209	muscle	object	new	_	_
25-28	4210-4211	.	_	_	_	_
